Short Interest in Pasithea Therapeutics Corp. (NASDAQ:KTTA) Rises By 641.7%

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 26,700 shares, a growth of 641.7% from the January 31st total of 3,600 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.6% of the company’s shares are short sold.

Pasithea Therapeutics Price Performance

Pasithea Therapeutics stock traded down $0.06 during trading hours on Friday, hitting $1.16. The company had a trading volume of 50,586 shares, compared to its average volume of 530,773. The company has a 50-day moving average price of $2.22 and a two-hundred day moving average price of $3.36. Pasithea Therapeutics has a 1 year low of $1.12 and a 1 year high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.